https://blueblood.com.tw/wp-content/uploads/2024/09/beautiful-transparent-water-drops-rain-water-soft-background-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302018-05-01 12:00:352025-06-27 09:46:07BB-101 Phase I clinical trial approved by the Ministry of Economic Affairs, receiving NT$15 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302018-04-01 12:00:302025-06-27 09:50:57NEGF (BB-101) received Taiwan FDA approval for clinical trials and began Phase I clinical trials at 3 medical centers in Taiwan.
Completed cGMP 300L clinical active pharmaceutical ingredient production.
BB-101 Phase I clinical trial approved by the Ministry of Economic Affairs, receiving NT$15 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
NEGF (BB-101) received Taiwan FDA approval for clinical trials and began Phase I clinical trials at 3 medical centers in Taiwan.